logo
Quantum Adds LTO-10 to Scalar Tape for Highest Capacity and Scale

Quantum Adds LTO-10 to Scalar Tape for Highest Capacity and Scale

Yahoo6 days ago

Quantum Corporation QMCO has announced full support for LTO Ultrium Generation 10 full-height tape drives across its leading Scalar tape library platforms—including Scalar i7 RAPTOR, Scalar i6 and Scalar i6000. This advancement cements Quantum's role at the forefront of scalable, cyber-resilient and cost-efficient archival storage solutions.
LTO-10 provides unmatched data density with native capacities of 30 TB per LTO-10 cartridge (up to 75 TB compressed at a 2.5:1 ratio). When combined with Quantum's intelligent tape automation and management software, it offers the lowest total cost of ownership, along with powerful cyber protections, making it ideal for enterprises seeking long-term archiving at scale in today's data-intensive environment.
Quantum, together with IBM and HPE, is a long-standing member of the LTO Consortium, which oversees the development, licensing and certification of LTO technology. This includes the company's ActiveScale object storage for cold data, StorNext file system for automated archival workflows and DXi backup appliances for long-term retention—all designed to deliver seamless performance from ingest to archive.
Notably, the newly introduced Scalar i7 RAPTOR was purpose-built to take full advantage of LTO-10 capabilities, delivering up to 60 PB of native capacity per rack—over three times the density of current market alternatives. These innovations lead to significant savings in space, power and cooling, translating to 70% lower operational costs. Enhanced by Quantum-exclusive features like Ransom Block, Tape Blocking and Active Vault, Scalar solutions offer robust air-gapped protection against cyber threats such as ransomware.
Quantum Corporation price-consensus-chart | Quantum Corporation Quote
Quantum highlighted the transformative role of LTO-10 within its integrated storage ecosystem, stating that when integrated with Scalar i7 RAPTOR, its S3-compatible ActiveScale platform transforms into a Glacier-class on-prem archive—capable of 60 PB per frame and up to 70% cost savings at exabyte scale.
LTO-10 drives offer high-speed data transfer at up to 400 MB/s and support multiple connectivity options, including 32 Gb Fibre Channel and 12 Gb SAS. With support for active optical cables up to 100 meters, these drives provide unmatched deployment flexibility. LTO-10 also eliminates the need for media calibration, simplifying workflows and enhancing efficiency. Quantum is accepting orders for LTO-10-based solutions across its Scalar and ActiveScale platforms, with shipments expected to begin later this quarter.
Recently, Quantum announced that Canal 13, one of Chile's premier broadcasters, has implemented a fully integrated content storage and management solution powered by Quantum's Myriad and ActiveScale platforms. This deployment marks a significant step in modernizing Canal 13's media infrastructure by eliminating storage silos and unifying production and archival systems into a streamlined, scalable and resilient workflow.
QMCO is a leading provider of end-to-end data management solutions. It offers solutions for capturing, sharing and preserving digital assets over the entire data lifecycle. It caters to leading organizations in life sciences, government, media and entertainment, research and industrial technology verticals. Its premium Myriad and ActiveScale products continue to witness healthy demand trends.
In January 2025, Quantum enhanced its Quantum Myriad all-flash file system, offering the first-ever in-place scaling with automatic data leveling. These upgrades provide greater flexibility and adaptability, allowing customers to effectively manage the evolving storage needs of the artificial intelligence (AI) era. In December 2024, Quantum extended support for the NVIDIA GPUDirect Storage capability by introducing an advanced parallel file system client for its Myriad all-flash file system.
Quantum's continuous efforts to elevate cyber resiliency for modern enterprises through fresh launches and collaborations bode well. In October 2024, QMCO's flagship ActiveScale platform expanded its Veeam Ready qualifications. Veeam Software supports Quantum's ActiveScale 7.0, which includes all-flash solutions for rapid ransomware recovery and reported ActiveScale Cold Storage for budget-friendly, air-gapped retention in the Veeam Archive Tier.
In the fiscal third quarter of 2025, ActiveScale experienced notable growth. Myriad continued to drive innovation by partnering with an AI pioneer, fusing quantum computing-inspired algorithms and AI/ML (machine learning) to solve complex challenges.
On May 6, 2025, Quantum announced preliminary financial results for the fourth quarter of fiscal 2025. Based on unaudited figures, the company expects to report revenues between $65 million and $67 million, aligning with prior guidance of $66 million, plus or minus $2 million. Gross margin is anticipated to be around 44%, with a 1% margin of variance. The company also projects a GAAP net loss of approximately $3.5 million, with a possible fluctuation of $1 million.
Quantum plans to release its full financial results for the fourth quarter and fiscal 2025 in mid-June 2025.
QMCO currently carries a Zacks Rank #3 (Hold). Shares of the company have surged 35.9% in the past year against the Computer-Storage Devices industry's decline of 31.4%.
Image Source: Zacks Investment Research
Some better-ranked stocks from the broader technology space are Ubiquiti Inc. UI, InterDigital, Inc. IDCC and Teradata Corporation TDC. UI, IDCC and TDC carry a Zacks Rank #2 (Buy). You can the complete list of today's Zacks #1 (Strong Buy) Rank stocks here.
UI's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 29.93%. In the last reported quarter, Ubiquiti delivered an earnings surprise of 61.29%. Its shares have surged 176.8% in the past year.
IDCC earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing in one, with the average surprise being 160.15%. InterDigital's long-term earnings growth rate is 15%. Its shares have jumped 88.1% in the past year.
Teradata's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 24.63%. In the last reported quarter, TDC delivered an earnings surprise of 15.79%. Its shares have decreased 33.1% in the past year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teradata Corporation (TDC) : Free Stock Analysis Report
InterDigital, Inc. (IDCC) : Free Stock Analysis Report
Quantum Corporation (QMCO) : Free Stock Analysis Report
Ubiquiti Inc. (UI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top 10 Strategic Imperatives for Oil and Gas Decarbonization in 2025
Top 10 Strategic Imperatives for Oil and Gas Decarbonization in 2025

Yahoo

timea day ago

  • Yahoo

Top 10 Strategic Imperatives for Oil and Gas Decarbonization in 2025

Decarbonization and digital transformation are reshaping the global energy industry, unlocking growth for oil and gas (O&G). As companies transition towards net-zero emissions, they face pricing, security, and disruption challenges. This study outlines the top 10 strategic imperatives for O&G's 2025 decarbonization. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Top 10 Strategic Imperatives in the Global Oil and Gas Industry, 2025" report has been added to digital transformation, and technology innovation have accelerated significantly in the past 5 years. The global energy industry is experiencing an unprecedented transition, and this change is bringing exciting new growth opportunities to the oil and gas (O&G) industry. However, the shift to a net-zero future concerning carbon emissions means many companies are also challenged by pricing, energy security, and industry disruption. The energy industry has scarcely been out of the news headlines for the past few years, specifically regarding price fluctuations, supply challenges, security issues, environmental impact, and growth in global demand. The main challenge for today's O&G industry is balancing the transition to net zero while meeting the demand for fossil fuels as efficiently and sustainably as possible. The competitive landscape influencing the future O&G industry is also changing. Innovation, market transformation, ambitious sustainability goals, and disruptive business models are driving the changes. This study lists and evaluates the top 10 strategic imperatives that the publisher has identified for the decarbonization of the global O&G industry in Topics Covered: Top 10 Strategic Imperatives in the Global Oil and Gas Industry, 2025 Quantum Computing for Reservoir Simulation Adoption of Carbon Capture Storage CCS Technologies Robotics for Automated Drilling and Repairs AI-driven Asset Management for Predictive Maintenance Cross-industry IoT Platforms for Operational Efficiency Managing Workforce Transitions due to Automation Geopolitical Shifts Affecting Energy Diplomacy Expansion of Biofuel Production Capabilities Environmental Regulations Reshaping Global Operations Using Drones and AI for Pipeline Inspection and Maintenance For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Tebra launches ambient documentation solution for healthcare providers
Tebra launches ambient documentation solution for healthcare providers

Yahoo

timea day ago

  • Yahoo

Tebra launches ambient documentation solution for healthcare providers

Tebra, a platform for independent healthcare providers, has introduced AI Note Assist, an ambient documentation solution designed to optimise clinical note-taking processes. This HIPAA-compliant tool is integrated into Tebra's existing electronic health record (EHR) system and aims to reduce the time spent on documentation by up to 50%. It allows independent healthcare providers to focus more on patient care. Tebra chief product and technology officer Kyle Ryan said: 'The launch of AI Note Assist is a significant milestone in our mission to empower independent practices. 'Our own research shows that 82% of independent providers believe more patient time is their key competitive advantage over large healthcare networks. We're delivering powerful, affordable AI tools that help providers reclaim that advantage by working efficiently, reducing burnout, and focusing on what matters most- delivering exceptional patient care. 'We expect AI Note Assist to save our customers thousands of administrative hours while significantly improving provider satisfaction.' AI Note Assist operates by listening to patient visits and automatically generating structured, editable clinical notes. For accuracy, the solution has been tested clinically and validated by practicing providers, verifying its trustworthiness in real-world settings. This innovation enables healthcare professionals to complete documentation tasks in half the usual time. The tool supports various clinical documentation formats, such as Therapy Initial and Progress notes, SOAP notes, and psychiatric notes. It also provides ICD-10 codes suggestions depending on the details of the conversation. Providers have control over the documentation process with the ability to examine, amend, and approve notes, thus maintaining clinical precision and completeness. Tebra customers can immediately access AI Note Assist via the company's existing platform, with no need to install additional hardware or software. "Tebra launches ambient documentation solution for healthcare providers" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Yahoo

timea day ago

  • Yahoo

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ('Cook MyoSite') to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, 'We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.' Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella's Board of Directors, added, 'Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.' About Cook MyoSite Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection and expansion of human skeletal muscle cells for the treatment of various disorders. In addition to operating several regulated clinical studies, Cook MyoSite provides a range of custom services, including modified cell samples to contract manufacturing arrangements, procurement and processing of muscle cells from specific donor populations, custom media formulations, CMO/CDMO arrangements and QC analytical testing and assay development. Learn more about Cook MyoSite at About Lipella Pharmaceuticals Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking StatementsThis press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals PCG AdvisoryJeff Ramsonjramson@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store